magnify.png
Mg Chart.png

Management of ESRD is complicated by hyperphosphatemia (the accumulation of phosphates in the body due to the inability of dialysis patients to excrete phosphate). This increases the risk of abnormal mineral and bone metabolism (MBD) and the risk of (sudden) death from cardiovascular disease. ​

Management of hyperphosphatemia depends on three approaches:

  1. Use of phosphate binders (the cornerstone);

  2. Dietary phosphate restriction (a significant hurdle for patients with Western diets); and

  3. Removal of phosphates during dialysis.

Adherence to each of these approaches presents challenges to CKD patients. Those with co-morbidities (such as diabetes, hypertension, etc.) already endure medication-related “pill burden”. Patient-specific factors such as age, gender, genetic background, culture, and cost of treatments add more problems.

Calcium salts are effective, inexpensive, and widely used phosphate binders. A recent review suggests calcium acetate is the most cost-effective phosphate-binding therapy for first-line use in dialysis patients. However, in acidic environments, calcium acetate is converted to acetic acid, a volatile organic acid with an irritating odor and repugnant taste. In contrast, calcium succinate binds phosphate equally well in vitro and is converted to succinic acid, a nonvolatile, tasteless organic acid in the citric acid cycle.

Present Day

Since 2004, European nephrologists have recognized that multi-year treatment of hyperphosphatemia with an oral tablet made up of a combination of 110 mg calcium (as calcium acetate) and 60 mg of magnesium (as magnesium carbonate) (“Ca/Mg”) rapidly and significantly low­ered serum phosphate without increasing serum calcium or raising serum magnesium levels beyond the normal range. Of note, investigators concluded that Ca/Mg is not inferior to sevelamer, a preferred current standard of care for hyper­phosphatemia in many dialysis centers.

See Outcomes of the CALMAG trial from five European countries

Ca/Mg vs. Sevelamer

GI absorption of diet-derived phosphate may be lowered and controlled by cations such as calcium and magnesium. Since both cations bind phosphate, addition of magnesium may provide physiological benefits not seen with calcium alone.

Changing The Picture

On Target 
For Phosphate Binding

Management of ESRD is
Complicated by Hyperphosphatemia
Download Our Latest White Paper

Partner With Us

At BioLink, we are always looking for terrific partners for our suite of products and patented molecules who can help us effectively reach appropriate patients and the clinicians who treat them. If you have an interest in Phosveda or any other BioLink assets, please reach out to us at info@phosveda.com or 919-678-9478.

 

Learn more here...

Download Our Latest White Paper

The information and reference materials contained in this document are intended  solely for the general education of the reader. The document is intended to provide  pertinent data to assist you in forming your own conclusions and making decisions. This document should not be considered an endorsement of the information provided nor is it intended for treatment purposes and is not a substitute for professional  evaluation and diagnosis. Additionally, this information is not intended to advocate any indication, dosage or other claim that is not covered, if applicable, in an FDA- approved label.

®

BioLink  |  250 Quade Drive  |  Cary, NC 27513  |  Phone: 1-919-678-9478  

BioLink LinkdIn